Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Lung Neoplasms trials

The registry lists 24 Lung Neoplasms studies with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor. 13 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 11Phase 3 2No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor TherapyNot yet recruitingNCT07596524
• Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLCRecruitingNCT07120282Phase 2
• A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung CancerRecruitingNCT07026669
• Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06793813Phase 2
• Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the SurgeryRecruitingNCT06483698
• Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruitingNCT06452433Phase 2
• Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world DataRecruitingNCT06314542
• The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung CancerRecruitingNCT06287320
• Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung CancersRecruitingNCT06255197
• Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Not yet recruitingNCT06198907Phase 2
• The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLCNot yet recruitingNCT05904015Phase 2
• LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung CancerRecruitingNCT05886439Phase 1/2
• Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC PatientsRecruitingNCT05443646Phase 2
• Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant ImmunotherapyActive, not recruitingNCT07256002
• Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLCCompletedNCT07186855
• HA-WBRT-SIB for Brain Metastasis of Lung CancerCompletedNCT06289023Phase 2
• Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC TreatmentStatus unknownNCT04970043Not applicable
• To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung CancerCompletedNCT04671303Phase 2
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung CancerStatus unknownNCT04213937Phase 2
• Single-port, Two-port Versus Three-port VATS on Non-small Cell Lung CancerStatus unknownNCT02992353Not applicable
• Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung CancerStatus unknownNCT02933294Not applicable
• Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLCCompletedNCT02688036Phase 3
• Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung CancerStatus unknownNCT01024712Phase 2